Clinical Trials Directory

Trials / Unknown

UnknownNCT00543478

Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome

Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
42 (estimated)
Sponsor
Aga Khan University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Probiotics are friendly bacteria normally present in food products like yogurt whereas irritable bowel syndrome is a longstanding functional disorder characterized by abdominal pain and altered bowel habits either diarrhea or constipation dominant without a definitive etiology. Study Hypothesis:Does probiotics(Saccharomyces boulardii improves daily bowel symptoms and quality of life in patients with diarrhea dominant irritable bowel syndrome?

Detailed description

Irritable bowel syndrome (IBS) is a common functional disorder and may lead to impaired social and personal function and can diminish quality of life.While the precise pathophysiology of IBS remains to be elucidated, dysmotility and altered visceral sensory perception are currently the most popular hypothesis. There has been a suggestion that some patients with IBS may harbor bacterial overgrowth leading to low grade inflammation, immune activation, and their symptoms may be ameliorated by its eradication.Probiotics, defined as live or attenuated bacteria or micro organism that confer a significant health benefit to the host. * I. Firstly, probiotic organism exert antibacterial and antiviral effects. * II. Probiotics could alter the composition of the gut flora, either directly through augmentation of commensal or indirectly through a reduction in pathogen related inflammation or bacterial fermentation. Trial protocol: Phase 1: placebo BID (1 week),both arms Phase 2: Randomization by pharmacy, placebo vs. active drug (6 weeks) Phase 3: placebo BID (1 week), both arms -III. Probiotics have been demonstrated to exert anti-inflammatory effects at mucosal surfaces by reducing mucosal inflammation, decreasing immune mediated activation of enteric motor and sensory neurons and modifying neural traffic between the gut and central nervous system. Saccharomyces Boulardii is a probiotic yeast and its role for the treatment of IBS has not been extensively investigated.

Conditions

Interventions

TypeNameDescription
DRUGSaccharomyces boulardii250mg, twice a day in sachets, for 8 weeks
DRUGMethyl cellulose powder (low viscosity)twice a day sachets for 10 weeks

Timeline

Start date
2007-10-01
Completion
2008-07-01
First posted
2007-10-15
Last updated
2007-10-15

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT00543478. Inclusion in this directory is not an endorsement.